169 related articles for article (PubMed ID: 24379381)
21. Doxorubicin-loaded iron oxide nanoparticles for glioblastoma therapy: a combinational approach for enhanced delivery of nanoparticles.
Norouzi M; Yathindranath V; Thliveris JA; Kopec BM; Siahaan TJ; Miller DW
Sci Rep; 2020 Jul; 10(1):11292. PubMed ID: 32647151
[TBL] [Abstract][Full Text] [Related]
22. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
[TBL] [Abstract][Full Text] [Related]
23. Beneficial effects of growth hormone-releasing hormone agonists on rat INS-1 cells and on streptozotocin-induced NOD/SCID mice.
Zhang X; Cui T; He J; Wang H; Cai R; Popovics P; Vidaurre I; Sha W; Schmid J; Ludwig B; Block NL; Bornstein SR; Schally AV
Proc Natl Acad Sci U S A; 2015 Nov; 112(44):13651-6. PubMed ID: 26474831
[TBL] [Abstract][Full Text] [Related]
24. New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor.
Kanashiro-Takeuchi RM; Szalontay L; Schally AV; Takeuchi LM; Popovics P; Jaszberenyi M; Vidaurre I; Zarandi M; Cai RZ; Block NL; Hare JM; Rick FG
Oncotarget; 2015; 6(12):9728-39. PubMed ID: 25797248
[TBL] [Abstract][Full Text] [Related]
25. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.
Alba M; Fintini D; Sagazio A; Lawrence B; Castaigne JP; Frohman LA; Salvatori R
Am J Physiol Endocrinol Metab; 2006 Dec; 291(6):E1290-4. PubMed ID: 16822960
[TBL] [Abstract][Full Text] [Related]
26. The effect of GHRH antagonists on human glioblastomas and their mechanism of action.
Pozsgai E; Schally AV; Zarandi M; Varga JL; Vidaurre I; Bellyei S
Int J Cancer; 2010 Nov; 127(10):2313-22. PubMed ID: 20162575
[TBL] [Abstract][Full Text] [Related]
27. The growth hormone-releasing hormone (GHRH) antagonist JV-1-36 inhibits proliferation and survival of human ectopic endometriotic stromal cells (ESCs) and the T HESC cell line.
Annunziata M; Grande C; Scarlatti F; Deltetto F; Delpiano E; Camanni M; Ghigo E; Granata R
Fertil Steril; 2010 Aug; 94(3):841-9. PubMed ID: 19524226
[TBL] [Abstract][Full Text] [Related]
28. Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice.
Stangelberger A; Schally AV; Varga JL; Zarandi M; Szepeshazi K; Armatis P; Halmos G
Clin Cancer Res; 2005 Jan; 11(1):49-57. PubMed ID: 15671527
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and structure-activity studies on novel analogs of human growth hormone releasing hormone (GHRH) with enhanced inhibitory activities on tumor growth.
Zarandi M; Cai R; Kovacs M; Popovics P; Szalontay L; Cui T; Sha W; Jaszberenyi M; Varga J; Zhang X; Block NL; Rick FG; Halmos G; Schally AV
Peptides; 2017 Mar; 89():60-70. PubMed ID: 28130121
[TBL] [Abstract][Full Text] [Related]
30. Antagonistic actions of analogs related to growth hormone-releasing hormone (GHRH) on receptors for GHRH and vasoactive intestinal peptide on rat pituitary and pineal cells in vitro.
Rekasi Z; Varga JL; Schally AV; Halmos G; Groot K; Czompoly T
Proc Natl Acad Sci U S A; 2000 Feb; 97(3):1218-23. PubMed ID: 10655511
[TBL] [Abstract][Full Text] [Related]
31. Effects of combined long-term treatment with a growth hormone-releasing hormone analogue and a growth hormone secretagogue in the growth hormone-releasing hormone knock out mouse.
Fintini D; Alba M; Schally AV; Bowers CY; Parlow AF; Salvatori R
Neuroendocrinology; 2005; 82(3-4):198-207. PubMed ID: 16601359
[TBL] [Abstract][Full Text] [Related]
32. A method for evaluation of activity of antagonistic analogs of growth hormone-releasing hormone in a superfusion system.
Rekasi Z; Schally AV
Proc Natl Acad Sci U S A; 1993 Mar; 90(6):2146-9. PubMed ID: 8460121
[TBL] [Abstract][Full Text] [Related]
33. Actions and Potential Therapeutic Applications of Growth Hormone-Releasing Hormone Agonists.
Schally AV; Zhang X; Cai R; Hare JM; Granata R; Bartoli M
Endocrinology; 2019 Jul; 160(7):1600-1612. PubMed ID: 31070727
[TBL] [Abstract][Full Text] [Related]
34. Partial biological characterization of cancer stem-like cell line (WJ(2)) of human glioblastoma multiforme.
Wang J; Wang X; Jiang S; Lin P; Zhang J; Wu Y; Xiong Z; Ren JJ; Yang H
Cell Mol Neurobiol; 2008 Nov; 28(7):991-1003. PubMed ID: 18350379
[TBL] [Abstract][Full Text] [Related]
35. Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers.
Letsch M; Schally AV; Busto R; Bajo AM; Varga JL
Proc Natl Acad Sci U S A; 2003 Feb; 100(3):1250-5. PubMed ID: 12538852
[TBL] [Abstract][Full Text] [Related]
36. Ghrelin and growth hormone (GH) secretagogues potentiate GH-releasing hormone (GHRH)-induced cyclic adenosine 3',5'-monophosphate production in cells expressing transfected GHRH and GH secretagogue receptors.
Cunha SR; Mayo KE
Endocrinology; 2002 Dec; 143(12):4570-82. PubMed ID: 12446584
[TBL] [Abstract][Full Text] [Related]
37. Suppression of tumor growth by growth hormone-releasing hormone antagonist JV-1-36 does not involve the inhibition of autocrine production of insulin-like growth factor II in H-69 small cell lung carcinoma.
Kiaris H; Schally AV; Varga JL
Cancer Lett; 2000 Dec; 161(2):149-55. PubMed ID: 11090963
[TBL] [Abstract][Full Text] [Related]
38. Growth hormone-releasing hormone promotes survival of cardiac myocytes in vitro and protects against ischaemia-reperfusion injury in rat heart.
Granata R; Trovato L; Gallo MP; Destefanis S; Settanni F; Scarlatti F; Brero A; Ramella R; Volante M; Isgaard J; Levi R; Papotti M; Alloatti G; Ghigo E
Cardiovasc Res; 2009 Jul; 83(2):303-12. PubMed ID: 19293247
[TBL] [Abstract][Full Text] [Related]
39. Growth hormone responses to growth hormone-releasing hormone (1-29)-NH2 and a D-Ala2 analog in normal men.
Barron JL; Coy DH; Millar RP
Peptides; 1985; 6(3):575-7. PubMed ID: 2866496
[TBL] [Abstract][Full Text] [Related]
40. Continuous 24-hour intravenous infusion of recombinant human growth hormone (GH)-releasing hormone-(1-44)-amide augments pulsatile, entropic, and daily rhythmic GH secretion in postmenopausal women equally in the estrogen-withdrawn and estrogen-supplemented states.
Evans WS; Anderson SM; Hull LT; Azimi PP; Bowers CY; Veldhuis JD
J Clin Endocrinol Metab; 2001 Feb; 86(2):700-12. PubMed ID: 11158034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
